Revisões Sistemáticas

M-A | Testes não invasivos para fibrose avançada podem reduzir a necessidade de biópsia em pacientes com doença hepática gordurosa não alcoólica.

3 Set, 2021 | 11:01h

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis – Gut

Comentário no Twitter

The long, winding and expensive road leading to highly sensitive and specific noninvasive Dx of #NASH @Gut_BMJ https://t.co/ToIkF3yTAU

— Daniel J Drucker (@DanielJDrucker) May 25, 2021

M-A de estudos randomizados | Efetividade da manobra de Valsalva (MV) modificada em adultos com taquicardia supraventricular (TSV) – “A metanálise mostrou uma taxa significativamente maior de conversão para ritmo sinusal com MV modificada em comparação à MV padrão em pacientes com TSV (odds ratio = 4,36; 95% intervalo de confiança, 3.30–5.76; P < 0.001).”

26 Ago, 2021 | 12:24h

Effectiveness of the modified Valsalva manoeuvre in adults with supraventricular tachycardia: a systematic review and meta-analysis – European Journal of Emergency Medicine (link para o resumo – $ para o texto completo)

Conteúdo relacionado: Randomized Trial: Standard Valsalva vs. Modified Valsalva for Cardioversion of SVT (estudos e comentários sobre o tema)

Vídeo: Modified Valsalva manoeuvre for supraventricular tachycardia – The Lancet

Prevenção de natimortos: quais são as evidências mais recentes?

25 Ago, 2021 | 12:55h

Preventing stillbirth: What’s the latest evidence? – Evidently Cochrane

Coleção especial: Stillbirth prevention and respectful bereavement care – Cochrane Library

Comentário no Twitter (fio – clique para saber mais)

New @CochraneLibrary Special Collection on #stillbirth prevention and respectful bereavement care: https://t.co/NW37SaUhr3 1/5#stillborn #babyloss #miscarriage #pregnancyloss #infantloss #pregnancyandinfantloss pic.twitter.com/mzIe3Sttwk

— The Cochrane Library (@CochraneLibrary) August 24, 2021

M-A | Agonistas receptores de GLP-1 reduzem eventos cardiovasculares adversos maiores, mortalidade por todas as causas, admissão hospitalar por insuficiência cardíaca e piora na função renal em pacientes com diabetes tipo 2.

23 Ago, 2021 | 12:58h

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)

Conteúdo relacionado: Guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.

M-A | O papel dos inibidores de SGLT2 na insuficiência cardíaca.

23 Ago, 2021 | 12:56h

The Role of SGLT2 Inhibitors in Heart Failure: A Systematic Review and Meta-Analysis – Cardiology Research and Practice

Conteúdos relacionados:

E SC Position Paper: Cardiac, renal, and metabolic effects of SGLT2 inhibitors.

Guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.

Summary: SGLT2 inhibitors and GLP-1 receptor agonists established and emerging indications.

M-A: SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure.

Meta-analysis: Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with Type 2 diabetes

#ESCCongress – [Abstract Only] SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

[Abstract Only] Randomized Trial: SGLT2 Inhibitor Improves Outcomes in Patients with Heart Failure Even in the Absence of Diabetes

M-A | Dose necessária de drogas antipsicóticas para prevenção de recaídas em pacientes com esquizofrenia estável.

20 Ago, 2021 | 12:19h

Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis – JAMA Psychiatry (gratuito por tempo limitado)

Comentários no Twitter

Crucial literature review on optimal antipsychotic dosing for long term maintenance in #Schizophrenia.

Conclusion: Seek Goldilocks "just right"- definitely not high because of bad side effects, but not so low as to risk relapse.

Often easier said than done. https://t.co/RBBPBMzn9D

— Allen Frances (@AllenFrancesMD) August 20, 2021

Doses higher than 5mg/day risperidone equivalent are not more effective for relapse prevention than lower doses in #schizophrenia. But caution is required at the lower end of the dose-response curve where relapse risk disproportionally increases https://t.co/kQcnuRtzYU

— JAMA Psychiatry (@JAMAPsych) August 19, 2021

M-A | Prevalência, tratamento e impacto da doença pulmonar obstrutiva crônica na fibrilação atrial.

20 Ago, 2021 | 12:18h

Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients – European Heart Journal (link para o resumo – $ para o texto completo)

Comentário no Twitter

AF-COMET Meta-analysis showed #COPD is common in #AF, being found in 13% of patients
📌⬆️ burden of comorbidities & worse outcomes
📌More than a two-fold ⬆️ risk of all-cause death
📌⬆️ Risk of CV death and major bleedinghttps://t.co/fLAuGkQAX1 @ESC_Journals @SchakrabartiEP pic.twitter.com/50OSfACH84

— Henry Han, MBBS, MD (@HanCardiomd) August 2, 2021

M-A de estudos randomizados | O efeito de maior ou menor aporte proteico em pacientes criticamente doentes – “Nesses pacientes, um alto aporte diário de proteína não esteve associado com qualquer melhora nos desfechos clínicos ou centrados no paciente.”

20 Ago, 2021 | 12:16h

The effect of higher versus lower protein delivery in critically ill patients: a systematic review and meta-analysis of randomized controlled trials – Critical Care

Superfícies de apoio para o tratamento de úlceras de pressão: quais escolher?

18 Ago, 2021 | 12:24h

Support surfaces for managing pressure ulcers: which to choose? – Evidently Cochrane

Revisão sistemática | Corticosteroides sistêmicos para tratamento de COVID-19.

17 Ago, 2021 | 11:39h

Systemic corticosteroids for the treatment of COVID‐19 – Cochrane Library

Resumo: Are corticosteroids given orally or by injection an effective treatment for people with COVID-19? – Cochrane Library